ProShare Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

ProShare Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-923	Closed	-$17K	–	1632
2016 Q1	$17K	Sell	923 -174	-16%	-$3.35K	﹤0.01%	1575
2015 Q4	$29K	Buy	1,097 +379	+53%	+$13.2K	﹤0.01%	1695
2015 Q3	$33K	Sell	718 -233	-25%	-$8.79K	﹤0.01%	1419
2015 Q2	$31K	Sell	951 -505	-35%	-$14.7K	﹤0.01%	1635
2015 Q1	$46K	Sell	1,456 -155	-10%	-$5.25K	﹤0.01%	1875
2014 Q4	$61K	Sell	1,611 -1,375	-46%	-$37.8K	﹤0.01%	1902
2014 Q3	$79K	Sell	2,986 -677	-18%	-$17.9K	﹤0.01%	2207
2014 Q2	$108K	Sell	3,663 -2,390	-39%	-$77.3K	﹤0.01%	2339
2014 Q1	$224K	Buy	+6,053	New	+$230K	﹤0.01%	2445
2013 Q4	–	Sell	-3,780	Closed	-$200K	–	2111
2013 Q3	$200K	Buy	3,780 +303	+9%	+$17.7K	﹤0.01%	2200
2013 Q2	$186K	Buy	+3,477	New	+$174K	﹤0.01%	2066

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ProShare Advisors's NAVB Position: Q2 2016 in Review

ProShare Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 923 shares — an estimated $17K sold.

ProShare Advisors first reported a position in NAVB in Q2 2013 and held it in 11 quarters. The position peaked at $224K in Q1 2014. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

ProShare Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
ProShare Advisors sold 923 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $17K.
ProShare Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 11 quarters.
ProShare Advisors's Navidea Biopharmaceuticals Inc. position peaked at $224K in Q1 2014.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on ProShare Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.